NCT06979648

Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels

Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels: A Randomized Double-Blind Parallel Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Qualia Life Sciences · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older. Approximately 100 participants with baseline RBC magnesium levels below 6.0 mg/dL will be randomly assigned to receive either Qualia Magnesium+ or a placebo. Participants will take 2 capsules daily in the evening, with or without food, for a duration of 12 weeks. The primary outcome is the between-group change in RBC magnesium levels from baseline to Week 12. Secondary outcomes include assessments of sleep quality, perceived stress, magnesium status, and safety and tolerability. Data collection will occur through lab bloodwork and electronic questionnaires.

Conditions

• Magnesium Deficiency

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Qualia Magnesium+®	Qualia Magnesium+® manufactured by Qualia Life Sciences
DIETARY_SUPPLEMENT	Placebo	Rice Flour

Timeline

• Start date: 2025-05-21
• Primary completion: 2025-08-21
• Completion: 2025-09-21
• First posted: 2025-05-20
• Last updated: 2025-05-20

Locations

1 site across 1 country: United States